var data={"title":"Metronidazole (topical): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Metronidazole (topical): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/390070?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=metronidazole-topical-patient-drug-information\" class=\"drug drug_patient\">see &quot;Metronidazole (topical): Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=metronidazole-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Metronidazole (topical): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770975\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>MetroCream;</li>\n      <li>Metrogel;</li>\n      <li>MetroGel-Vaginal;</li>\n      <li>MetroLotion;</li>\n      <li>Noritate;</li>\n      <li>Nuvessa;</li>\n      <li>Rosadan;</li>\n      <li>Vandazole</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770976\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Flagyl Cream;</li>\n      <li>MetroCream;</li>\n      <li>Metrogel;</li>\n      <li>MetroLotion;</li>\n      <li>Nidagel;</li>\n      <li>Noritate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771007\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Topical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771178\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial vaginosis:</b> Intravaginal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0.75% (Vandazole): One applicatorful (~37.5 mg metronidazole) intravaginally once daily for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0.75% (MetroGel-vaginal, other products): One applicatorful (~37.5 mg metronidazole) intravaginally once or twice daily for 5 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1.3%: One applicatorful (~65 mg metronidazole) intravaginally as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rosacea:</b> Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0.75%: Apply and rub a thin film twice daily, morning and evening, to entire affected areas after washing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1%: Apply thin film to affected area once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Trichomoniasis: </b>Intravaginal: 10% (Flagyl Cream [Canadian product]): Insert one applicatorful (equal to metronidazole 500 mg) intravaginally once or twice daily for 10 or 20 consecutive days (even during menses)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771179\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25234258\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25234259\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; use with caution in severe hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771215\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MetroCream: 0.75% (45 g) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Noritate: 1% (60 g) [contains methylparaben, propylparaben, trolamine (triethanolamine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rosadan: 0.75% (45 g) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.75% (45 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metrogel: 1% (55 g, 60 g) [contains methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rosadan: 0.75% (45 g) [contains edetate disodium, methylparaben, propylene glycol, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.75% (45 g); 1% (55 g, 60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, Vaginal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MetroGel-Vaginal: 0.75% (70 g) [contains edetate disodium, methylparaben, propylene glycol, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nuvessa: 1.3% (5 g [DSC]) [contains benzyl alcohol, methylparaben, polyethylene glycol, propylene glycol, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nuvessa: 1.3% (5 g) [contains benzyl alcohol, methylparaben, propylene glycol, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vandazole: 0.75% (70 g) [contains methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.75% (70 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rosadan: 0.75% [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rosadan: 0.75% [contains edetate disodium, methylparaben, propylene glycol, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Lotion, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MetroLotion: 0.75% (59 mL) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.75% (59 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8770978\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49283107\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream, Vaginal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flagyl cream: 10% [contains methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel, Vaginal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">NidaGel: 0.75% (70 g) [contains edetate disodium, methylparaben, propylene glycol, propylparaben]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771200\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical: No disulfiram-like reactions have been reported after <b>topical</b> application, although metronidazole can be detected in the blood. Apply to clean, dry skin. Cosmetics may be used after application (wait at least 5 minutes after using lotion).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intravaginal: For vaginal use only.  Applicator may be inserted in any comfortable position.  Hold the applicator by the barrel, gently insert into the vagina as far as possible without causing discomfort..  Press the plunger until it stops and withdraw the applicator. Patients should not use intravaginal products (eg, tampons, douches) or engage in vaginal intercourse for the duration of treatment.  Discard applicator after use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0.75%: Administer once in morning and evening if using twice daily; if daily, use at bedtime.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">1.3%: Administer as a single dose at bedtime.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">10% (Flagyl cream [Canadian product]): Administer once or twice daily; do not use applicator after the 7<sup>th</sup> month of pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771026\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacterial vaginosis:</b> Vaginal gel: Treatment of bacterial vaginosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Rosacea:</b> Topical: Treatment of inflammatory lesions and erythema of rosacea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Trichomoniasis:</b> Flagyl cream [Canadian product]: Treatment of trichomoniasis in females</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771048\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>Topical:</b> Frequency not always defined: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Burning sensation of skin (&le;2%), erythema (&le;2%), skin irritation (&le;2%), xeroderma (&le;2%), acne vulgaris, contact dermatitis, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Metallic taste, nausea, unusual taste, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Hypersensitivity reaction </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Numbness of extremities, peripheral neuropathy, tingling of extremities</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Eye irritation </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Flu-like symptoms</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Vaginal:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: Genitourinary: Vaginal discharge (12%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (2% to 5%), dizziness (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Gastrointestinal distress (7%), nausea and vomiting (2% to 4%), metallic taste (2%; or unusual taste), abdominal cramps (1%), decreased appetite (1%), diarrhea (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Cervical candidiasis (10%; or vaginitis), vulvovaginal irritation (9%), vulvovaginal candidiasis (6%), pelvic pain (3%), vulvovaginal pruritus (2%), dysmenorrhea (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing and/or case reports: Bloating, dark urine, depression, fatigue, functional gastric bloating, increased thirst, pruritus, skin rash, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771034\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to metronidazole, parabens, or other ingredients of the formulation or other nitroimidazole derivatives; use of disulfiram within the past 2 weeks; use of alcohol or propylene glycol during therapy or within 24 hours (Nuvessa only) or 3 days of therapy discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flagyl cream [Canadian product]: Additional contraindications: Active neurological disorders; history of blood dyscrasia, hypothyroidism or hypoadrenalism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nidagel [Canadian product]: Additional contraindications: Use during the first trimester of pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771035\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Carcinogenic: Possibly carcinogenic based on animal data. Unnecessary use should be avoided.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS effects: Aseptic meningitis, encephalopathy, seizures, and neuropathies (peripheral and optic) have been reported with systemic metronidazole, especially with increased doses and chronic treatment; peripheral neuropathy has also been reported with topical products; monitor and consider discontinuation of therapy if signs/symptoms occur. Use with caution in patients with CNS diseases. Discontinue immediately if abnormal neurologic signs develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Eye irritation: May cause tearing of the eye; avoid contact with the eyes. In the event of accidental contact, wash out immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with severe liver impairment due to potential accumulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection. Approximately 6% to 10% of women treated with the vaginal gel developed <i>Candida</i> vaginitis during or immediately after treatment. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Blood dyscrasias: Use with caution in patients with or history of blood dyscrasias.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Vaginal gel: Disulfiram-like reaction to ethanol has been reported with systemic metronidazole and may occur with the vaginal gel; consider avoidance of alcoholic beverages during therapy with vaginal gel. Do not administer the vaginal gel to patients who have taken disulfiram within the past 2 weeks. Patients should avoid vaginal intercourse during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771053\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771054\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9590&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Alcohol (Ethyl). A disulfiram-like reaction may occur.  Management: Warn patients and monitor for signs and symptoms of a disulfiram-like reaction if patients consume alcohol while using topical metronidazole. Some manufacturers of vaginal metronidazole products list alcohol use within 24 to 72 hours as a contraindication<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disulfiram: MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Disulfiram. In particular, the risk for CNS toxicities such as psychosis may be increased.  Management: Warn patients and monitor for the development of serious CNS toxicity if topical metronidazole is used in a patient taking disulfiram. Some manufacturers of vaginal metronidazole products list disulfiram use within 2 weeks as a contraindication.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Lopinavir. Specifically, the use of topical metronidazole with lopinavir/ritonavir solution (which contains 42% alcohol) may result in a disulfiram-like reaction. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: MetroNIDAZOLE (Topical) may enhance the adverse/toxic effect of Tipranavir. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771029\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771030\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Metronidazole crosses the placenta and rapidly distributes into the fetal circulation following oral administration. The amount of metronidazole available systemically following topical application is less in comparison to oral doses. Although the vaginal products are not indicated for use in pregnant patients, bacterial vaginosis has been associated with adverse pregnancy outcomes; current guidelines recommended metronidazole for the treatment of symptomatic bacterial vaginosis in pregnancy (CDC [Workowski 2015]).  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9773196\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Metronidazole is excreted in breast milk following oral administration and can be detected in concentrations similar to the maternal serum. The amount of metronidazole available systemically following topical application is less in comparison to oral doses. According to the manufacturer, the decision to continue or discontinue breast-feeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother; nursing women may consider pumping and discarding their milk during therapy and 24 hours after therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771139\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">After diffusing into the organism, interacts with DNA to cause a loss of helical DNA structure and strand breakage resulting in inhibition of protein synthesis and cell death in susceptible organisms</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771141\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Topical: Concentrations achieved systemically after application of the 1 g topical gel and cream are &lt;1% of those obtained after a 250 mg oral dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vaginal gel: Concentrations achieved systemically after application of  5 g vaginal gel (containing either 37.5 mg or 65 mg metronidazole) are ~2 % of those obtained after a 500 mg oral dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8771217\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (MetroCream External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75% (45 g): $750.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (MetroNIDAZOLE External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75% (45 g): $315.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Noritate External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (60 g): $2,347.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Rosadan External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75% (45 g): $462.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Metrogel External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (55 g): $451.74</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (MetroGel-Vaginal Vaginal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75% (70 g): $328.81</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (MetroNIDAZOLE External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75% (45 g): $319.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1% (55 g): $277.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (MetroNIDAZOLE Vaginal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75% (70 g): $146.71</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Nuvessa Vaginal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.3% (5 g): $220.99</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Rosadan External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75% (45 g): $462.41</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Vandazole Vaginal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75% (70 g): $163.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Rosadan External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75% (cream) (1): $462.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75%(gel) (1): $462.41</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lotion</b> (MetroLotion External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75% (59 mL): $862.68</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lotion</b> (MetroNIDAZOLE External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.75% (59 mL): $247.14</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14190112\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acea Gel (GB, IE);</li>\n      <li>Epaq (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Geloderm (CL);</li>\n      <li>Li Fu (CN);</li>\n      <li>Metroderme (PT);</li>\n      <li>Metrogel (CR, DE, DO, GB, GT, HN, NI, PA, SV, TW);</li>\n      <li>Metrogyl (LK);</li>\n      <li>Metrogyl Gel (TH, VN);</li>\n      <li>Metrosa (EE, HR, LV);</li>\n      <li>Nidazea (BE);</li>\n      <li>Robaz (GR, PH, TH);</li>\n      <li>Rosaced gel (BE, FR);</li>\n      <li>Rosiced (PT);</li>\n      <li>Roza (TR);</li>\n      <li>Rozacreme (FR);</li>\n      <li>Rozagel (FR);</li>\n      <li>Rozamet (HR);</li>\n      <li>Rozex (AR, AT, AU, BE, BR, CH, CO, CZ, DK, EE, ES, FI, FR, GB, HK, IE, IL, IT, JP, KR, KW, LB, LU, LV, MY, NL, NO, NZ, PE, PL, PY, SA, SE, SG, UY, VE, ZA);</li>\n      <li>Trogel (BD);</li>\n      <li>Zidoval (IL);</li>\n      <li>Zyomet Gel (MT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-topical-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-topical-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flagyl Cream (metronidazole) [product monograph]. Laval, Quebec, Canada: Sanofi-aventis Canada Inc; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-topical-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metrogel (metronidazole) [prescribing information]. Thornhill, Ontario, Canada: Galderma Canada Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metrogel Vaginal (metronidazole) [prescribing information]. Scottsdale, AZ: Medicis; January 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metronidazole Gel [prescribing information]. Bridgewater, NJ: Valeant; March 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nidagel (metronidazole) [product monograph]. Laval, Quebec, Canada: Valeant Canada LP; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nuvessa (metronidazole) [prescribing information]. Irvine, CA: Allergan USA, Inc.; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vandazole (metronidazole) [prescribing information]. Maple Grove, MN: Upsher-Smith; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metronidazole-topical-drug-information/abstract-text/26042815 /pubmed\" target=\"_blank\" id=\"26042815 \">26042815 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9590 Version 169.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F8770975\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F8770976\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F8771007\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F8771178\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F8771179\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F25234258\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F25234259\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F8771215\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F8770978\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F49283107\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F8771200\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F8771026\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F8771048\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F8771034\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F8771035\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F8771053\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F8771054\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F8771029\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F8771030\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9773196\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F8771139\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F8771141\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F8771217\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F14190112\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9590|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=metronidazole-topical-patient-drug-information\" class=\"drug drug_patient\">Metronidazole (topical): Patient drug information \t</a></li><li><a href=\"topic.htm?path=metronidazole-topical-pediatric-drug-information\" class=\"drug drug_pediatric\">Metronidazole (topical): Pediatric drug information</a></li></ul></div></div>","javascript":null}